Abstract
Glioblastoma (GBM), a WHO grade IV malignant glioma, is the most common and lethal adult primary brain tumor. Median survival rates range from 12-15 months. The current standard of care for GBM has evolved from resection followed by adjuvant radiotherapy to resection, concurrent adjuvant chemotherapy (temozolomide) and radiation, and additional adjuvant chemotherapy. The expression of specific molecular biomarkers, especially O-6 – methylguanine methyltransferase (MGMT) status, may determine the response of the tumor to treatment, and helps in identifying the magnitude of benefit from this regimen. By identifying further biological subtypes of GBM at the molecular level, specific targeted therapies could be developed and used in the future for more individualized therapeutic regimens. This article will review the current therapies for GBM and the investigation of new molecular and targeted therapies, such as EGFR inhibitors, mTOR/PI3Kinase inhibitors, and anti-angiogenesis agents.
Keywords: GBM, glioblastoma, temozolomide, molecular therapy, radiation, MGMT
Reviews on Recent Clinical Trials
Title: Current Therapeutic Paradigms in Glioblastoma
Volume: 5 Issue: 1
Author(s): Allison Quick, Disha Patel, Mersiha Hadziahmetovic, Arnab Chakravarti and Minesh Mehta
Affiliation:
Keywords: GBM, glioblastoma, temozolomide, molecular therapy, radiation, MGMT
Abstract: Glioblastoma (GBM), a WHO grade IV malignant glioma, is the most common and lethal adult primary brain tumor. Median survival rates range from 12-15 months. The current standard of care for GBM has evolved from resection followed by adjuvant radiotherapy to resection, concurrent adjuvant chemotherapy (temozolomide) and radiation, and additional adjuvant chemotherapy. The expression of specific molecular biomarkers, especially O-6 – methylguanine methyltransferase (MGMT) status, may determine the response of the tumor to treatment, and helps in identifying the magnitude of benefit from this regimen. By identifying further biological subtypes of GBM at the molecular level, specific targeted therapies could be developed and used in the future for more individualized therapeutic regimens. This article will review the current therapies for GBM and the investigation of new molecular and targeted therapies, such as EGFR inhibitors, mTOR/PI3Kinase inhibitors, and anti-angiogenesis agents.
Export Options
About this article
Cite this article as:
Quick Allison, Patel Disha, Hadziahmetovic Mersiha, Chakravarti Arnab and Mehta Minesh, Current Therapeutic Paradigms in Glioblastoma, Reviews on Recent Clinical Trials 2010; 5 (1) . https://dx.doi.org/10.2174/157488710790820544
DOI https://dx.doi.org/10.2174/157488710790820544 |
Print ISSN 1574-8871 |
Publisher Name Bentham Science Publisher |
Online ISSN 1876-1038 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Abnormal Choline Phospholipid Metabolism in Breast and Ovary Cancer:Molecular Bases for Noninvasive Imaging Approaches
Current Medical Imaging Human Amnion–Derived Cells as a Reliable Source of Stem Cells
Current Molecular Medicine Peptides as Tight Junction Modulators
Current Pharmaceutical Design Proinflammatory Cytokines in Breast Cancer: Mechanisms of Action and Potential Targets for Therapeutics
Current Drug Targets Meet Our Co-Editor
Current Signal Transduction Therapy Recent Advances in Optical Molecular Imaging and its Applications in Targeted Drug Delivery
Current Drug Targets p53 Regulation of Energy Metabolism and Mitochondria Regulation of p53 in Cancer Cells: An Insight into the Role of Manganese Superoxide Dismutase
Current Pharmaceutical Biotechnology Hsp90: A Novel Target for Cancer Therapy
Current Topics in Medicinal Chemistry Applications of Lipid based Formulation Technologies in the Delivery of Biotechnology-based Therapeutics
Current Pharmaceutical Biotechnology The Use of SIFT-MS to Investigate Headspace Aldehydes as Markers of Lipid Peroxidation
Current Analytical Chemistry Yeast as a Powerful Model System for the Study of Apoptosis Regulation by Protein Kinase C Isoforms
Current Pharmaceutical Design Non-coding RNAs in Exosomes: New Players in Cancer Biology
Current Genomics Cancer Gene Therapy by Adenovirus-Mediated Gene Transfer
Current Gene Therapy APE1/Ref-1Role in Redox Signaling: Translational Applications of Targeting the Redox Function of the DNA Repair/Redox Protein APE1/Ref-1
Current Molecular Pharmacology Exosomes: A Promising Factor Involved in Cancer Hypoxic Microenvironments
Current Medicinal Chemistry Targeting EGFR for Treatment of Glioblastoma: Molecular Basis to Overcome Resistance
Current Cancer Drug Targets Synthesis of 99mTc-Nimotuzumab with Tricarbonyl Ion: in vitro and in vivo Studies
Current Radiopharmaceuticals C-Methionine PET/CT in Central Nervous System Tumours: A Review
Current Radiopharmaceuticals Targeting SREBP-1-driven Lipid Metabolism to Treat Cancer
Current Pharmaceutical Design Peptide-based Radiopharmaceuticals for Targeted Tumor Therapy
Current Medicinal Chemistry